



## ESC Declaration of Interest Report

### 2020 ESC Guidelines for the management of adult congenital heart disease

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the [ESC Declaration and Management of Conflict of Interest Policy](#) and accompanying [2012 ESC Policy statement : Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education](#).

Any form of the following characteristics may disqualify an individual from serving on a Guidelines committee, if related to the guideline topic:

- Part-time employment or salary
- Stock ownership
- Holding of a patent which generates revenues
- Receipt of royalties for intellectual property

The following additional characteristics may also disqualify an individual for the positions of CPG Chairperson, Guidelines Task Force Chairperson and Guidelines Review Coordinator:

- Personally received payments from healthcare industry of 10,000€ or higher per year.
- Payments from healthcare industry of 10,000€ or higher per year, made to one's institution/hospital or to other legal bodies which have generated a direct or indirect personal benefit/asset.

## 2020 ESC Guidelines for the management of adult congenital heart disease - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert             | Type of Relationship with Industry   |
|--------------------|--|
| Babu-Narayan Sonya | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Research funding (personal).<br/>- British Heart Foundation : Charity funded cardiovascular research grant</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.<br/>- British Heart Foundation Associate Medical Director since October 2018 -UK charity with advocacy for public and patients with cardiovascular disease and for CVD research support</p>   |
|                    | <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself<br/>- I work for the UK charity and research funder the British Heart Foundation.</p>   |
| Baumgartner Helmut | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br/>- Actelion : targeted PAH therapy<br/>- Edwards Lifesciences : transcatheter valve implantation</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br/>- Actelion : targeted PAH therapy<br/>- Abbott : transcatheter mitral valve repair (Mitraclip)<br/>- Edwards Lifesciences : transcatheter valve implantation</p> |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert             | Type of Relationship with Industry   |
|--------------------|--|
| Baumgartner Helmut | <b>2018</b> - Medtronic Foundation : transcatheter valve implantation  |
|                    | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- Actelion : pulmonary hypertension  |
| Budts Werner       | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Occlutech : PFO and ASD closure<br><br>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Servier : Atherosclerosis<br>- Medtronic : Ceraflex - Venus valve<br>- Occlutech : Interventional cardiology<br>- St Jude Medical Abbott : Interventional cardiology<br>- Boston Scientific : LAA closure<br>- Pfizer : Lipids<br>- Actelion : Pulmonary hypertension |
|                    | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- Occlutech : PFO and ASD closure  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert          | Type of Relationship with Industry  |
|-----------------|---|
| Budts Werner    | <p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Occlutech : Interventional cardiology</li> <li>- St Jude Medical Abbott : Interventional cardiology</li> <li>- Medtronic : Venus valve</li> </ul>  |
| Chessa Massimo  | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : PFO Closure</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Interventional proctoring</li> <li>- Occlutech : Interventional proctoring</li> <li>- Gore : Interventional proctoring</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Meeting IMAC: organisation</li> </ul> |
| De Backer Julie | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : ERT Fabry disease</li> </ul>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Diller Gerhard Paul | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Daiichi Sankyo : Anticoagulation<br>- Actelion : Pulmonary Hypertension                  |
|                     | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- Daiichi Sankyo : Anticoagulation<br>- Actelion : Pulmonary hypertension  |
| lung Bernard        | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Boehringer Ingelheim : Anticoagulants<br>- Edwards Lifesciences : Heart valve prostheses |
|                     | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities. For yourself<br>- Abbott : Cardiovascular devices  |
| Kluin Jolanda       | <b>2018</b><br><br>Nothing to be declared  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Kluin Jolanda     | <b>2019</b><br><br>Nothing to be declared  |
| Lang Irene Marthe | <b>2018</b><br><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Actelion : Pulmonary Hypertension drugs<br>- United Therapeutics : Pulmonary Hypertension drugs<br>- Ferrer Internacional : Pulmonary Hypertension drugs<br>- MSD : Pulmonary Hypertension drugs<br>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension drugs<br><br>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Actelion : Pulmonary Hypertension drugs<br>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension drugs<br><br><hr/> <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- Actelion : Pulmonary Hypertension drugs<br>- United Therapeutics : Pulmonary Hypertension drugs<br>- Ferrer Internacional : Pulmonary Hypertension drugs<br>- MSD : Pulmonary Hypertension drugs<br>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension drugs |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Lang Irene Marthe | <p><b>2019</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities. For members of your household<br/>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself<br/>- Actelion : Pulmonary hypertension</p>  |
| Meijboom Folkert  | <p><b>2018</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.<br/>- Education - Co-owner of "Smart Heart Imaging and Teaching" , that organizes the annual European courses on echocardiography for congenital heart disease and the congenital TEE course.</p> <hr/> <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself<br/>- Education - Smart Heart Imaging and Teaching is a company that organizes annual teaching courses for Echocardiography for Congenital Heart disease in Europe. I am 1/3 owner.</p> |
| Moons Philip      | <p><b>2018</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2019</b></p> <p>Nothing to be declared</p>  |
| Mulder Barbara Jm | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.<br/>- Actelion : PAH</p>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Mulder Barbara Jm       | <b>2019</b><br>Nothing to be declared  |
| Oechslin Erwin          | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Actelion : Pulmonary Vasodilators / Pulmonary Hypertension       |
|                         | <b>2019</b><br>Nothing to be declared  |
| Roos-Hesselink Jolien W | <b>2018</b><br>Nothing to be declared  |
|                         | <b>2019</b><br>Nothing to be declared  |
| Schwerzmann Markus      | <b>2018</b><br>Financial Declaration<br><br>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Actelion : Pulmonary Hypertension<br>- Merck Sharp & Dohme : Pulmonary Hypertension<br>- Orpha Suisse : Pulmonary Hypertension |



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Schwerzmann Markus | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> <li>- Orpha Suisse : Pulmonary Hypertension</li> </ul> <p>Research funding (personal) from healthcare industry. For yourself</p> <ul style="list-style-type: none"> <li>- Orpha Suisse : Pulmonary hypertension</li> </ul>   |
| Soendergaard Lars  | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : TAVI</li> <li>- Abbott : TAVI, LAAC</li> <li>- Boston Scientific : TAVI, LAAC</li> <li>- Edwards Lifesciences : TAVI, TMVR</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : TAVI</li> <li>- Medtronic : TAVI</li> <li>- Abbott : TAVI, LAAC</li> <li>- Boston Scientific : TAVI, LAAC</li> </ul> <hr/> <p><b>2019</b></p> <p>Nothing to be declared</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert           | Type of Relationship with Industry   |
|------------------|--|
| Zeppenfeld Katja | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Mapping systems, catheters</li> <li>- Biosense Webster : Mapping systems, catheters</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : catheters, mapping systems</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Research electrophysiology</li> </ul> |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Aboyans Victor      | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Antithrombotic therapy</li> <li>- BMS/Pfizer Alliance : Antithrombotic therapy</li> <li>- NovoNordisk : Diabetes</li> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipid lowering therapy</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapy</li> </ul> |
| Ahmeti Artan        | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Alexander David     | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Amri Rachida        | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Bakhutashvili Zviad | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Balint Hajnalka     | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : PAH</li> </ul>   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Balint Hajnalka   | <b>2019</b><br>- MSD : PAH<br>- AOP Orphan Pharmaceuticals : PAH  |
| Bondue Antoine    | <b>2019</b><br>Other Positions of Influence<br><br>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself<br>- Board member of the Belgian Cardiology Ligue                    |
| Boughzela Essia   | <b>2019</b><br><br>Nothing to be declared   |
| Bouma Berto       | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Abbott : Mitraclip |
| Brida Margarita   | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- Pfizer : Travel meeting  |
| Bulatovic Nebojsa | <b>2019</b><br><br>Nothing to be declared   |
| Caruana Maryanne  | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- Bayer : ESC Congress 2019 congress attendance                              |
| Chesnov Jouri     | <b>2019</b><br><br>Nothing to be declared   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                        | Type of Relationship with Industry  |
|-------------------------------|---|
| Christodorescu Ruxandra Maria | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Pharma</li> <li>- Pfizer : Pharma</li> <li>- Servier : Pharma</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Pharma</li> </ul>  |
| Coats Louise                  | <p><b>2019</b></p> <p>Nothing to be declared</p>  |
| Coman Ioan Mircea             | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulants</li> <li>- Bayer AG : antithrombotic</li> <li>- Johnson &amp; Johnson : antithrombotic , PHT</li> <li>- Sanofi Aventis : dyslipidemia</li> <li>- Novartis : HF</li> <li>- Vifor International : iron deficiency</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulants</li> <li>- Bayer AG : antithrombotic</li> </ul> |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Coman Ioan Mircea | <b>2019</b> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : antithrombotic ,pht</li> <li>- Sanofi Aventis : dyslipidemia</li> <li>- Novartis : HF</li> <li>- Vifor International : iron deficiency</li> </ul>  |
| Corrado Domenico  | <b>2019</b><br><br>Nothing to be declared   |
| D'Alto Michele    | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- GlaxoSmithKline : Pulmonary hypertension</li> <li>- Ferrer Internacional : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> </ul> |
| de Groot Natasja  | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Boston Scientific : electrophysiology</li> </ul>   |
| Delgado Victoria  | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- GE Healthcare : 3-dimensional imaging workshop (2000 euro)</li> <li>- Medtronic : aortic stenosis (payment speaker fee 900 euro)</li> </ul>  |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Delgado Victoria  | <p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Bayer : diabetes - steering committee (750 euro)</li> <li>- Abbott Vascular : Mitraclip (payment speaker fee 1200 euro)</li> <li>- Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Aortic valve stenosis</li> <li>- Bayer : Heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abbott Vascular : Mitraclip</li> <li>- Edwards Lifesciences : Tricuspid valve</li> </ul>  |
| Di Salvo Giovanni | <p><b>2019</b></p> <p>Nothing to be declared</p>  |
| Dos Subira Laura  | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension</li> </ul> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For members of your household</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Heart Failure</li> <li>- Sanofi Aventis : Hypolipemiant</li> <li>- Bayer : Oral Anticoagulation</li> <li>- Boehringer-Ingelheim : Oral Anticoagulation</li> <li>- Pfizer : Oral Anticoagulation</li> </ul> |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Dos Subira Laura    | <p><b>2019</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For members of your household</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Heart Failure</li> <li>- Sanofi Aventis : Hypolipemiant</li> <li>- Bayer : Oral Anticoagulation</li> <li>- Boehringer-Ingelheim : Oral Anticoagulation</li> <li>- Pfizer : Oral Anticoagulation</li> </ul> |
| Eicken Andreas      | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic Foundation : proctor Melody valve</li> </ul>   |
| El Sayed Maiy Hamdy | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Ermel Raili         | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Participation in AATS Mitral Conclave 2019 and Annual meeting 2019</li> </ul>   |
| Ernst Sabine        | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Catheter ablation</li> </ul>  |



## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                            | Type of Relationship with Industry   |
|-----------------------------------|--|
| Ernst Sabine                      | <p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Medilumics : Catheter ablation</li> <li>- Stereotaxis : remote magnetic navigation</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Advisory board member for the Arrhythmia Alliance</li> </ul> |
| Estensen Mette-Elise              | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Fitzsimons Donna                  | <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of Scientific Advisory Board of Northern Ireland Chest Heart &amp; Stroke (Non-Paid)</li> </ul>  |
| Frogoudaki Alexandra              | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- ELPEN GREECE : GENERAL CARDIOLOGY</li> </ul>   |
| Gallego Garcia De Vinuesa Pastora | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul>   |
| Gatzoulis Michael                 | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> <li>- Elsevier : ACHD</li> </ul>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Giannakoulas George | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Merck A.E. : Chronic coronary artery disease</li> <li>- Menarini : Chronic coronary artery disease, Cardiovascular Disease</li> <li>- Astra Zeneca : Diabetes mellitus</li> <li>- Roche Diagnostics : Heart Failure</li> <li>- Novartis : Heart Failure, Cardiovascular Disease</li> <li>- Amgen : Hyperlipidemia</li> <li>- Servier : Hyperlipidemia</li> <li>- MSD : Hyperlipidemia-Pulmonary Hypertension</li> <li>- Actelion : Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- Lilly : Pulmonary Hypertension</li> <li>- United Therapeutics : Pulmonary Hypertension</li> <li>- Galenica Greece : Pulmonary Hypertension</li> <li>- Elpen Pharmaceuticals : Pulmonary Hypertension, Hyperlipidemia</li> <li>- Boehringer-Ingelheim : Thromboembolic Disease, Heart Failure</li> <li>- Bayer Healthcare : Thromboembolism, Chronic coronary artery disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Chronic coronary artery disease</li> <li>- Novartis : Heart Failure</li> <li>- Mylan Greece : Hyperlipidemia</li> </ul> |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Giannakoulas George | <b>2019</b> <ul style="list-style-type: none"> <li>- Lilly : Pulmonary Hypertension</li> <li>- United Therapeutics : Pulmonary Hypertension</li> <li>- Leo Pharma : Thromboembolism</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Atrial Fibrillation</li> </ul>  |
| Greutmann Matthias  | <b>2019</b> <p>Nothing to be declared</p>   |
| Grigoryan Svetlana  | <b>2019</b> <p>Nothing to be declared</p>   |
| Guldbrand Dorte     | <b>2019</b> <p>Nothing to be declared</p>   |
| Gumbiene Lina       | <b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For members of your household</p> <ul style="list-style-type: none"> <li>- Actelion. Johnson &amp;Johnson affiliate : speaker and advisory board fees</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Board member and head of WG on ACHD and PH of Lithuanian Society of Cardiology</li> </ul> |
| Hadjisavva Urania   | <b>2019</b> <p>Nothing to be declared</p>   |
| Hammoudi Naima      | <b>2019</b> <p>Nothing to be declared</p>   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Heymans Stephane  | <b>2019</b><br><br>Nothing to be declared  |
| Hoerer Juergen    | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Bristol Myers Squibb : speaker fee  |
| Houyel Lucile     | <b>2019</b><br><br>Nothing to be declared  |
| Imanov Galib      | <b>2019</b><br><br>Nothing to be declared  |
| Johansson Bengt   | <b>2019</b><br><br>Nothing to be declared  |
| Jondeau Guillaume | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Novartis : heart failure<br><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- Novartis : ESC meeting |
| Kaneva Anna       | <b>2019</b><br><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- AbbiVie : AEPC meeting  |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Kaneva Anna       | <b>2019</b> - Pierre-Fabre : Infantile haemangioma Shering days  |
| Katus Hugo        | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Bayer Vital : Anticoagulants</li> <li>- Astrazeneca : Antiplatelet</li> <li>- Novartis : Heart Failure Therapies</li> <li>- Boston Scientific : PCI</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulations</li> <li>- Roche Diagnosticsarker : Biomarker</li> </ul> |
| Ladouceur Magalie | <b>2019</b><br><br>Nothing to be declared  |
| Landmesser Ulf    | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Abbott : Advisory Board fees</li> <li>- Medicines Company : Advisory Board fees</li> <li>- Bayer : Speaker fee</li> <li>- Amgen : Speaker fees</li> <li>- Sanofi Aventis : Speaker fees</li> </ul>  |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Landmesser Ulf       | <b>2019</b><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br>- Bayer AG : Research Grant  |
| Lewis Basil S        | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Novo-Nordisk : Diabetes<br>- Merck Sharp & Dohme : Heart failure<br>- CSL Behring : Lipidology, Secondary prevention<br><br>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Pfizer : Diabetes<br>- Merck Sharp & Dohme : Heart failure<br>- Kowa : Lipidology<br>- Resverlogix : Lipidology. secondary prevention |
| Lockhart Christopher | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- Actelion : ESC travel   |
| Lunegova Olga        | <b>2019</b><br><br>Nothing to be declared  |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                | Type of Relationship with Industry   |
|-----------------------|--|
| Lyon Alexander        | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Clinigen Group : Cardio-Oncology, Dexrazoxane</li> <li>- Roche Pharma : Cardio-Oncology, Herceptin, Perjeta</li> <li>- Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib</li> <li>- Pfizer : Cardiotoxicity of cancer drugs for renal cancer and chronic myeloid leukaemia: sunitinib, axitinib, bosutinib</li> <li>- Novartis : Heart failure, Entresto, breast cancer - ribociclib</li> <li>- Servier : Ivabradine, S44121, Pixantrone</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - HEART FAILURE - Stock option (&lt;1%) in Heartfelt Technologies Inc Stock option (1%) in Brainstorm Inc Stock option (1%) in Myocardial Solutions Inc</li> </ul> |
| Mair Johannes Michael | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Congenital and Structural Interventions, Frankfurt 2019</li> </ul>   |
| Moiseeva Olga         | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : speaker fees</li> <li>- Janssen-Cilag : speaker fees</li> </ul>   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Moiseeva Olga           | <p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : investigator</li> <li>- Janssen-Cilag : investigator</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : ESC congress 2019, Paris, France</li> <li>- Janssen-Cilag : PH forum 2019, Berlin, Germany</li> </ul>  |
| Mueller Christian Eugen | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Novartis : Heart Failure</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> </ul> |



## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Mueller Christian Eugen | <b>2019</b> <ul style="list-style-type: none"> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> </ul>   |
| Murrone Adriano         | <b>2019</b><br><br>Nothing to be declared  |
| Mylotte Darren          | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Biosensors : Coronary Stents</li> <li>- Boston Scientific : TAVI</li> <li>- Medtronic : TAVI</li> <li>- Microport : TAVI</li> </ul><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself <ul style="list-style-type: none"> <li>- Biosensors : Coronary Stents</li> <li>- Medtronic : TAVI</li> </ul> |
| Naser Nabil             | <b>2019</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Novartis : Uperio - Valsartan - Sacubitril</li> </ul>   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Nir Amiram              | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br/>- Actelion : Research grant</p>   |
| Petersen Steffen Erhard | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br/>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself<br/>- Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself<br/>- Member of the advocacy committee for the Society of Cardiovascular Magnetic Resonance (SCMR).</p> |
| Petronio Anna Sonia     | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br/>- Boston Scientific : Structural heart disease<br/>- Abbott : structural valve disease</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br/>- Medtronic : structural heart disease</p>   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Petronio Anna Sonia     | <b>2019</b><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br>- Abbott : coronary disease, valve disease<br>- GaDA : valve disease   |
| Popelova Jana Rubackova | <b>2019</b><br>Nothing to be declared  |
| Prokselj Katja          | <b>2019</b><br>Nothing to be declared  |
| Roffi Marco             | <b>2019</b><br>Financial Declaration<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br>- Boston Scientific : Stents<br>- Medtronic : Stents<br>- Biotronik : stents<br>- GE Healthcare : stents  |
| Rosenhek Raphael        | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Abbott : Valvular heart disease<br>- Edwards Lifesciences : Valvular heart disease<br>- Medtronic : Valvular heart disease<br>- Llvanova : Valvular heart disease |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert           | Type of Relationship with Industry   |
|------------------|--|
| Rudzitis Ainars  | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Hypertension</li> <li>- Boehringer - Ingelheim : NOAC</li> <li>- Sanofi Aventis : Rare diseases</li> <li>- Takeda Pharmaceuticals : Rare diseases</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi-Genzyme : Hypertrophic cardiomyopathy</li> </ul> |
| Saliba Zakhia    | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : All products</li> <li>- Lifetech : All products</li> </ul>   |
| Shlyakhto Evgeny | <p><b>2019</b></p> <p>Nothing to be declared</p>   |
| Simkova Iveta    | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension</li> </ul>  |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                            | Type of Relationship with Industry  |
|-----------------------------------|---|
| Simkova Iveta                     | <b>2019</b><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- Actelion : pulmonary hypertension   |
| Simpson Iain A                    | <b>2019</b><br>Nothing to be declared   |
| Sinisalo Juha                     | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Amgen : Hypercholesterolemia<br>- Abbott Vascular : Percutaneous closures                            |
| Sirenko Yuriy                     | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Takeda, Ferrer, Bayer, local manufacturers : Antihypertensive, pulmonary hypertension specific drugs |
| Sousa Uva Miguel                  | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities.For yourself<br>- Medtronic : Cardiothoracic Surgery   |
| Srbinovska-Kostovska Elizabeta    | <b>2019</b><br>Nothing to be declared   |
| Stojisic-Milosavljevic Anastazija | <b>2019</b><br>Nothing to be declared   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                         | Type of Relationship with Industry  |
|--------------------------------|---|
| Thambo Jean Benoit             | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : left atrial appendage closure</li> <li>- Abbott : patent foramen ovale closure / left atrial appendage closure</li> <li>- Medtronic : Transcatheter pulmonary valve implantation</li> </ul> <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> <li>- Pierre-Fabre : proliferating infantile haemangioma</li> </ul> |
| Tomkiewicz-Pajak Lidia         | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Macitentan</li> </ul>  |
| Torp-Pedersen Christian Tobias | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novo Nordisk : Grant for epidemiological studies</li> <li>- Bayer AG : Grant for randomised study</li> </ul>  |
| Touyz Rhian                    | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Hypertension</li> </ul>   |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                   | Type of Relationship with Industry  |
|--------------------------|---|
| Touyz Rhian              | <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- I am Editor in Chief of Clinical Science I am Deputy Editor of Hypertension</li> </ul>  |
| Van De Bruaene Alexander | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Echocardiography symposium</li> <li>- Menarini : Hypertension</li> <li>- Actelion : Pulmonary hypertension</li> </ul> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Diabeters</li> <li>- Janssen-Cilag : Diabetes</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Echocardiography</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For members of your household</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Diabetes</li> <li>- Medtronic : Insulin pump and sensor</li> </ul> |
| Wagner Kerstin           | <p><b>2019</b></p> <p>Nothing to be declared</p>  |

## 2020 ESC Guidelines for the management of adult congenital heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert          | Type of Relationship with Industry   |
|-----------------|--|
| Walther Claudia | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Cardiovascular</li> <li>- Abbott : Structural heart disease</li> </ul> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> <li>- Abbott : Structural heart disease</li> <li>- Boston Scientific : Structural heart disease</li> <li>- Edwards Lifesciences : Structural heart disease</li> </ul> |
| Zavatta Marco   | <p><b>2019</b></p> <p>Nothing to be declared</p>   |



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert         | Type of Relationship with Industry   |
|----------------|--|
| Aboyans Victor | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer : Antithrombotic therapy</li> <li>- BMS/Pfizer Alliance : Antithrombotic therapy</li> <li>- NovoNordisk : Diabetes</li> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipid lowering therapy</li> <li>- Sanofi Aventis : PAD</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : PAD</li> </ul> |
|                | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Antithrombotic therapy</li> <li>- BMS/Pfizer Alliance : Antithrombotic therapy</li> <li>- NovoNordisk : Diabetes</li> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipid lowering therapy</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapy</li> </ul>   |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert               | Type of Relationship with Industry  |
|----------------------|---|
| Baigent Colin        | <b>2018</b><br>Financial Declaration<br><br>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.<br>- Boehringer-Ingelheim : Empagliflozin<br>- Novartis : Sacubitril<br>- Pfizer : Sirolimus  |
|                      | <b>2019</b><br>Financial Declaration<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br>- Boehringer-Ingelheim : Empagliflozin   |
| Collet Jean-Philippe | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Bristol Myers Squibb : Apixaban<br>- Astra Zeneca : TICAGRELOR<br><br>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.<br>- Bristol Myers Squibb : apixaban<br>- Medtronic : COREVALVE |
|                      | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Astra Zeneca : Post-PCI antiplatelet traitement  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Collet Jean-Philippe | <p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul>  |
| Delgado Victoria     | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Mitraclip</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Echocardiography</li> <li>- Edwards Lifesciences : Transcatheter valve interventions</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : 3-dimensional imaging workshop (2000 euro)</li> <li>- Medtronic : aortic stenosis (payment speaker fee 900 euro)</li> <li>- Bayer : diabetes - steering committee (750 euro)</li> <li>- Abbott Vascular : Mitraclip (payment speaker fee 1200 euro)</li> <li>- Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Aortic valve stenosis</li> </ul> |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                 | Type of Relationship with Industry  |
|------------------------|---|
| Delgado Victoria       | <p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Bayer : Heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abbott Vascular : Mitraclip</li> <li>- Edwards Lifesciences : Tricuspid valve</li> </ul>   |
| Fitzsimons Donna       | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medscape : Heart failure</li> </ul> <hr/> <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> <li>- Member of Scientific Advisory Board of Northern Ireland Chest Heart &amp; Stroke (Non-Paid)</li> </ul> |
| Gale Christopher Peter | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS</li> <li>- Novartis : coronary artery disease</li> <li>- Bayer : coronary artery disease, AF</li> <li>- Vifor International : heart failure</li> <li>- Menarini : ischaemic heart disease</li> </ul>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                 | Type of Relationship with Industry  |
|------------------------|---|
| Gale Christopher Peter | <b>2018</b><br>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.<br>- Bristol Myers Squibb : Apixiban, AF   |
|                        | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- Astra Zeneca : ACS<br>- Daiichi Sankyo : AF<br>- Novartis : coronary artery disease<br>- Bayer : coronary artery disease, AF<br>- Vifor International : heart failure<br>- Menarini : ischaemic heart disease<br><br>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- BMS : AF<br>- Abbott : Diabetes<br>- National Institute for Health Research : MI<br>- British Heart Foundation : MI, AF<br>- Horizon 2020 : post MI sudden cardiac death<br><br>Travel and meeting support from healthcare industry, independent of the above activities. For yourself<br>- Daiichi Sankyo : AF<br>- Bayer Healthcare : AF, CAD<br>- National Institute for Health and Clinical Excellence : Indicator Advisory Committee |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                 | Type of Relationship with Industry  |
|------------------------|---|
| Gale Christopher Peter | <b>2019</b><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br>- Bristol Myers Squibb : Apixiban, AF   |
| Grobbee Diederick E    | <b>2018</b><br>Financial Declaration<br><br>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Amgen : advisory board<br>- Esperion : Steering ctt<br><br>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.<br>- Esperion : clinical trial lipids<br><br>Other Positions of Influence<br><br>Employment in healthcare industry (including part time) during the year for which you are declaring.<br>- chief scientific officer Julius Clinical Research Ltd (part-time) |
|                        | <b>2019</b><br>Financial Declaration<br><br>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself<br>- Amgen : advisory board<br>- Esperion : Steering ctt<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself<br>- Esperion : clinical trial lipids  |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Grobbee Diederick E | <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> <li>- Chief Scientific Officer Julius Clinical Academic Contract Research Organization Staff Member, University Medical Center Utrecht</li> </ul>   |
| Halvorsen Sigrun    | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Antithrombotic treatment</li> <li>- Astra Zeneca : Anti-thrombotic treatment</li> <li>- Boehringer-Ingelheim : Anti-thrombotic treatment</li> <li>- Pfizer : Anti-thrombotic treatment</li> <li>- Bayer AS : Anti-thrombotic treatment</li> <li>- Sanofi Aventis : Cholesterol lowering treatment</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Bristol Myers Squibb : Anticoagulation</li> </ul> |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Halvorsen Sigrun  | <b>2019</b> <ul style="list-style-type: none"> <li>- Bayer AS : Anticoagulation</li> <li>- Merck Sharp &amp; Dohme : Glucose lowering drugs</li> <li>- Sanofi Aventis : Lipid lowering treatment</li> </ul>   |
| Hindricks Gerhard | <b>2018</b> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Pacemaker, Ablation</li> <li>- Biosense Webster : Pacemaker, Ablation</li> <li>- Biotronik : Pacemaker, catheter</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Electrophysiology, arrhythmias</li> <li>- Abbott : Electrophysiology, arrhythmias</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group.</li> </ul> <hr/> <b>2019</b> <p>Nothing to be declared</p> |



## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert       | Type of Relationship with Industry   |
|--------------|--|
| Iung Bernard | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Boehringer Ingelheim : Anticoagulants<br>- Edwards Lifesciences : Heart valve prostheses   |
|              | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities. For yourself<br>- Abbott : Cardiovascular devices  |
| Juni Peter   | <b>2018</b><br>Financial Declaration<br><br>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.<br>- Astra Zeneca : Anti-platelet Therapy<br>- Biotronik : Drug-eluting stents<br>- Biosensors International Group : Drug-eluting stents<br>- The Medicines Company : Thrombin inhibitors<br><br>Other Positions of Influence<br><br>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.<br>- Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert     | Type of Relationship with Industry  |
|------------|---|
| Juni Peter | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Fresenius Nutrition : ECCO2R in COPD</li> <li>- Ava : Fertility App</li> <li>- Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> <li>- Director, Applied Health Research Centre, St. Michael's Hospital</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.</li> </ul> |
| Katus Hugo | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Bayer Vital : Anticoagulants</li> <li>- Astrazeneca : Antiplatelet</li> <li>- Roche Diagnostics : Biomar</li> </ul>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert         | Type of Relationship with Industry   |
|----------------|--|
| Katus Hugo     | <p><b>2018</b></p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Roche Diagnosticsarker : Biomarker</li> <li>- Daiichi Sankyo : Xarelto</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- President of the German Society of Cardiology</li> </ul>  |
|                | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Bayer Vital : Anticoagulants</li> <li>- Astrazeneca : Antiplatelet</li> <li>- Novartis : Heart Failure Therapies</li> <li>- Boston Scientific : PCI</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulations</li> <li>- Roche Diagnosticsarker : Biomarker</li> </ul> |
| Landmesser Ulf | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : Advisory Board fees</li> </ul>   |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Landmesser Ulf      | <p><b>2018</b></p> <ul style="list-style-type: none"> <li>- Medicines Company : Advisory Board fees</li> <li>- Amgen : Speaker fees</li> <li>- Sanofi Aventis : Speaker fees</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Research Grant</li> </ul>  |
|                     | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Advisory Board fees</li> <li>- Medicines Company : Advisory Board fees</li> <li>- Bayer : Speaker fee</li> <li>- Amgen : Speaker fees</li> <li>- Sanofi Aventis : Speaker fees</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Research Grant</li> </ul> |
| Leclercq Christophe | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : devices</li> <li>- Boston Scientific : devices</li> <li>- Medtronic : devices</li> <li>- Biotronik : devices</li> </ul>   |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Leclercq Christophe | <b>2018</b><br>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Biotronik : devices  |
|                     | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself<br>- Abbott : devices<br>- Boston Scientific : devices<br>- Medtronic : devices<br>- Biotronik : devices<br>- Microport : devices<br>- Zoll Medical : WCD  |
| Lettino Maddalena   | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Daiichi Sankyo : Anticoagulants<br>- Pfizer : Anticoagulants<br>- Bayer Healthcare : Antithrombotic agents, anticoagulants<br>- Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs<br>- Astra Zeneca : Antithrombotic agents, statins |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Lettino Maddalena | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulants</li> <li>- Daiichi Sankyo : anticoagulants</li> <li>- Pfizer : anticoagulants</li> <li>- Bristol Myers Squibb : anticoagulants</li> <li>- Amgen : lipid-lowering drugs</li> <li>- Sanofi Aventis : lipid-lowering drugs</li> </ul>  |
| Lewis Basil S     | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Pfizer : Antithrombotics</li> <li>- Astra Zeneca : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Astrazeneca : Antithrombotics</li> <li>- Astra Zeneca : Diabetes</li> <li>- Pfizer : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> </ul> |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert        | Type of Relationship with Industry   |
|---------------|--|
| Lewis Basil S | <b>2018</b> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> <li>- Resverlogix : Lipidology. secondary prevention</li> </ul>  |
|               | <b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- Resverlogix : Lipidology. secondary prevention</li> </ul> |
| Merkely Bela  | <b>2018</b> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT course</li> <li>- Abbott : CRT/ICD</li> <li>- Astra Zeneca : HF</li> <li>- Biotronik : ICD/CRT</li> </ul>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Merkely Bela            | <p><b>2018</b></p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiac rhythm management</li> <li>- Boston Scientific : CRT</li> </ul>  |
|                         | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT course</li> <li>- Abbott : CRT/ICD</li> <li>- Astra Zeneca : HF</li> <li>- Biotronik : ICD/CRT</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiac rhythm management</li> <li>- Boston Scientific : CRT</li> </ul> |
| Mueller Christian Eugen | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Indorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul>  |



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry  |
|-------------------------|---|
| Mueller Christian Eugen | <p><b>2018</b></p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Beckman Coulter : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Singulex : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> </ul>   |
|                         | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Novartis : Heart Failure</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry  |
|-------------------------|---|
| Mueller Christian Eugen | <p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> </ul>  |
| Petersen Steffen Erhard | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> <li>- Servier : Heart failure</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc.</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> </ul> |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Petersen Steffen Erhard | <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</li> </ul> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> <li>- Member of the advocacy committee for the Society of Cardiovascular Magnetic Resonance (SCMR).</li> </ul>   |
| Petronio Anna Sonia     | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Percutaneous Aortic and Mitral treatment</li> <li>- Medtronic : Percutaneous Aortic and mitral treatment</li> <li>- Abbott : Percutaneous Mitral treatment</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : TAVI research</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Structural heart disease</li> <li>- Abbott : structural valve disease</li> </ul> |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert                 | Type of Relationship with Industry   |
|------------------------|--|
| Petronio Anna Sonia    | <p><b>2019</b></p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : structural heart disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : coronary disease, valve disease</li> <li>- GaDA : valve disease</li> </ul>  |
| Priori Silvia Giuliana | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Cardiac device</li> </ul> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Audentes Rx : Gene therapy</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : antiarrhythmic drugs</li> </ul> <hr/> <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Cardiac Device</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Takeda Pharmamaceuticals : Anti-arrhythmic drugs</li> </ul> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Richter Dimitrios | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : aortic stenosis</li> <li>- Menarini : CAD- hypertension</li> <li>- Unipharm : hypertension-thrombosis</li> <li>- Abbott : lipids</li> <li>- Amgen : lipids</li> <li>- Servier : LIPIDS</li> <li>- Sanofi Aventis : Lipids</li> <li>- Lilly : Lipids</li> <li>- Unilever : lipids</li> <li>- Merck Sharp &amp; Dohme : lipids</li> <li>- Vianex : lipids</li> <li>- RAFARM : LIPIDS</li> <li>- ELPEN : LIPIDS-THROMBOSIS</li> <li>- Bayer Healthcare : Thrombosis</li> <li>- Leo Pharma : THROMBOSIS</li> <li>- NovaGEM CYPRUS : THROMBOSIS</li> </ul> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Richter Dimitrios | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : diabetes</li> <li>- Boehringer-Ingelheim : diabetes</li> <li>- Unipharma : hypertension-thrombosis</li> <li>- Amgen : lipids</li> <li>- Servier : LIPIDS</li> <li>- Sanofi Aventis : Lipids</li> <li>- Lilly : Lipids</li> <li>- Unilever : lipids</li> <li>- Merck Sharp &amp; Dohme : lipids</li> <li>- Vianex : lipids</li> <li>- Mylan : lipids</li> <li>- ELPEN : LIPIDS-THROMBOSIS</li> <li>- Bayer Healthcare : Thrombosis</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : LIPIDS</li> <li>- Bayer : THROMBOSIS</li> </ul> |
| Roffi Marco       | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Stents</li> </ul>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert           | Type of Relationship with Industry   |
|------------------|--|
| Roffi Marco      | <b>2018</b> <ul style="list-style-type: none"> <li>- Medtronic : Stents</li> <li>- Biotronik : stents</li> <li>- Terumo Inc : stents</li> <li>- Abbott Vascular : stents</li> </ul>  |
|                  | <b>2019</b> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Stents</li> <li>- Medtronic : Stents</li> <li>- Biotronik : stents</li> <li>- GE Healthcare : stents</li> </ul>   |
| Shlyakhto Evgeny | <b>2018</b> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Krka Pharma : Arterial Hypertension</li> <li>- Novartis : Arterial Hypertension, Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Atherosclerosis</li> <li>- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation</li> <li>- Pfizer : General Cardiology</li> </ul> |
|                  | <b>2019</b> <p>Nothing to be declared</p>  |
| Simpson Iain A   | <b>2018</b> <p>Nothing to be declared</p>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Simpson Iain A   | <b>2019</b><br>Nothing to be declared   |
| Sousa Uva Miguel | <b>2018</b><br>Financial Declaration<br><br>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Abott : Surgical Valves   |
|                  | <b>2019</b><br>Financial Declaration<br><br>Travel and meeting support from healthcare industry, independent of the above activities. For yourself<br>- Medtronic : Cardiothoracic Surgery  |
| Touyz Rhian      | <b>2018</b><br>Financial Declaration<br><br>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.<br>- Novartis : antihypertensive drugs<br>- Alnylam : antihypertensive drugs<br><br>Research funding (personal).<br>- British Heart Foundation : Hypertension research<br>- Medical Research Council, UK : Hypertension research<br><br>Other Positions of Influence<br><br>Membership or affiliation in political or advocacy groups working in the field of cardiology.<br>- American Heart Association International Society of Hypertension British Irish Hypertension Society |



## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Touyz Rhian       | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Hypertension</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- I am Editor in Chief of Clinical Science I am Deputy Editor of Hypertension</li> </ul>   |
| Windecker Stephan | <p><b>2018</b></p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> <li>- CSL Behring : Invasive Cardiology</li> <li>- Polares Medical : Invasive Cardiology</li> </ul> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Abbott : General Cardiology</li> <li>- Boston Scientific : General Cardiology</li> <li>- Edwards Lifesciences : General Cardiology</li> <li>- Medtronic : General Cardiology</li> <li>- Biotronik : General Cardiology</li> <li>- Amgen Inc : General Cardiology</li> <li>- Bristol Myers Squibb : General Cardiology</li> <li>- Bayer AG : General Cardiology</li> <li>- Sinomed : General Cardiology</li> </ul> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Windecker Stephan | <p><b>2018</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR</li> </ul>  |
|                   | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Amgen : Dyslipidemia</li> <li>- Johnson &amp; Johnson : Electrophysiology and General Cardiology</li> <li>- Daiichi Sankyo : General Cardiology</li> <li>- Terumo Inc : General Cardiology</li> <li>- Sanofi Aventis : General Cardiology</li> <li>- Bayer AG : General Cardiology</li> <li>- CSL Behring : General Cardiology</li> <li>- Cardinal health : General Cardiology</li> <li>- Guerbet AG : General Cardiology</li> <li>- Abbott : Invasive Cardiology</li> <li>- Boston Scientific : Invasive Cardiology</li> <li>- Edwards Lifesciences : Invasive Cardiology</li> <li>- Medtronic : Invasive Cardiology and Electrophysiology</li> <li>- Biotronik : Invasive Cardiology and Electrophysiology</li> </ul> |

## ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Windecker Stephan | <p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <p>- Deputy Editor JACC CV Intervention , Section Editor Uptodate, Course Director PCR</p> |